Click for best price
Oncology Immunotherapy Market Size, Share 2023
The global Oncology Immunotherapy market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.
This report aims to provide a comprehensive presentation of the global market for Oncology Immunotherapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncology Immunotherapy. This report contains market size and forecasts of Oncology Immunotherapy in global, including the following market information:
Global Oncology Immunotherapy Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Immune Checkpoint Inhibitors Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Oncology Immunotherapy include Bristol-Myers Squibb, Merck & Co, Roche AG, AstraZeneca, Sanofi S.A., Dendreon Pharmaceuticals, Novartis, Gilead Sciences Inc. and Merck KGaA, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Oncology Immunotherapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Oncology Immunotherapy Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Oncology Immunotherapy Market Segment Percentages, by Type, 2022 (%)
- Immune Checkpoint Inhibitors
- Cytokine-Based Immunotherapy
- Cancer Vaccines
- CAR-T Cell Therapy
- Other
Global Oncology Immunotherapy Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Oncology Immunotherapy Market Segment Percentages, by Application, 2022 (%)
- Hospitals
- Drugstores
- Others
Global Oncology Immunotherapy Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Oncology Immunotherapy Market Segment Percentages, By Region and Country, 2022 (%)
- North America (United States, Canada, Mexico)
- Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
- Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
- The Middle East and Africa (Middle East, Africa)
- South and Central America (Brazil, Argentina, Rest of SCA)
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Oncology Immunotherapy revenues in global market, 2018-2023 (estimated), ($ millions)
- Key companies Oncology Immunotherapy revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Bristol-Myers Squibb
- Merck & Co
- Roche AG
- AstraZeneca
- Sanofi S.A.
- Dendreon Pharmaceuticals
- Novartis
- Gilead Sciences Inc.
- Merck KGaA
Outline of Major Chapters:
Chapter 1: Introduces the definition of Oncology Immunotherapy, market overview.
Chapter 2: Global Oncology Immunotherapy market size in revenue.
Chapter 3: Detailed analysis of Oncology Immunotherapy company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Oncology Immunotherapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Oncology Immunotherapy Market, Global Outlook and Forecast 2023-2030 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
63 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Oncology Immunotherapy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Oncology Immunotherapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Oncology Immunotherapy Overall Market Size
2.1 Global Oncology Immunotherapy Market Size: 2022 VS 2030
2.2 Global Oncology Immunotherapy Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Oncology Immunotherapy Players in Global Market
3.2 Top Global Oncology Immunotherapy Companies Ranked by Revenue
3.3 Global Oncology Immunotherapy Revenue by Companies
3.4 Top 3 and Top 5 Oncology Immunotherapy Companies in Global Market, by Revenue in 2022
3.5 Global Companies Oncology Immunotherapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Oncology Immunotherapy Players in Global Market
3.6.1 List of Global Tier 1 Oncology Immunotherapy Companies
3.6.2 List of Global Tier 2 and Tier 3 Oncology Immunotherapy Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Oncology Immunotherapy Market Size Markets, 2022 & 2030
4.1.2 Immune Checkpoint Inhibitors
4.1.3 Cytokine-Based Immunotherapy
4.1.4 Cancer Vaccines
4.1.5 CAR-T Cell Therapy
4.1.6 Other
4.2 By Type - Global Oncology Immunotherapy Revenue & Forecasts
4.2.1 By Type - Global Oncology Immunotherapy Revenue, 2018-2023
4.2.2 By Type - Global Oncology Immunotherapy Revenue, 2024-2030
4.2.3 By Type - Global Oncology Immunotherapy Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Oncology Immunotherapy Market Size, 2022 & 2030
5.1.2 Hospitals
5.1.3 Drugstores
5.1.4 Others
5.2 By Application - Global Oncology Immunotherapy Revenue & Forecasts
5.2.1 By Application - Global Oncology Immunotherapy Revenue, 2018-2023
5.2.2 By Application - Global Oncology Immunotherapy Revenue, 2024-2030
5.2.3 By Application - Global Oncology Immunotherapy Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Oncology Immunotherapy Market Size, 2022 & 2030
6.2 By Region - Global Oncology Immunotherapy Revenue & Forecasts
6.2.1 By Region - Global Oncology Immunotherapy Revenue, 2018-2023
6.2.2 By Region - Global Oncology Immunotherapy Revenue, 2024-2030
6.2.3 By Region - Global Oncology Immunotherapy Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Oncology Immunotherapy Revenue, 2018-2030
6.3.2 US Oncology Immunotherapy Market Size, 2018-2030
6.3.3 Canada Oncology Immunotherapy Market Size, 2018-2030
6.3.4 Mexico Oncology Immunotherapy Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Oncology Immunotherapy Revenue, 2018-2030
6.4.2 Germany Oncology Immunotherapy Market Size, 2018-2030
6.4.3 France Oncology Immunotherapy Market Size, 2018-2030
6.4.4 U.K. Oncology Immunotherapy Market Size, 2018-2030
6.4.5 Italy Oncology Immunotherapy Market Size, 2018-2030
6.4.6 Russia Oncology Immunotherapy Market Size, 2018-2030
6.4.7 Nordic Countries Oncology Immunotherapy Market Size, 2018-2030
6.4.8 Benelux Oncology Immunotherapy Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Oncology Immunotherapy Revenue, 2018-2030
6.5.2 China Oncology Immunotherapy Market Size, 2018-2030
6.5.3 Japan Oncology Immunotherapy Market Size, 2018-2030
6.5.4 South Korea Oncology Immunotherapy Market Size, 2018-2030
6.5.5 Southeast Asia Oncology Immunotherapy Market Size, 2018-2030
6.5.6 India Oncology Immunotherapy Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Oncology Immunotherapy Revenue, 2018-2030
6.6.2 Brazil Oncology Immunotherapy Market Size, 2018-2030
6.6.3 Argentina Oncology Immunotherapy Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Oncology Immunotherapy Revenue, 2018-2030
6.7.2 Turkey Oncology Immunotherapy Market Size, 2018-2030
6.7.3 Israel Oncology Immunotherapy Market Size, 2018-2030
6.7.4 Saudi Arabia Oncology Immunotherapy Market Size, 2018-2030
6.7.5 UAE Oncology Immunotherapy Market Size, 2018-2030
7 Oncology Immunotherapy Companies Profiles
7.1 Bristol-Myers Squibb
7.1.1 Bristol-Myers Squibb Company Summary
7.1.2 Bristol-Myers Squibb Business Overview
7.1.3 Bristol-Myers Squibb Oncology Immunotherapy Major Product Offerings
7.1.4 Bristol-Myers Squibb Oncology Immunotherapy Revenue in Global Market (2018-2023)
7.1.5 Bristol-Myers Squibb Key News & Latest Developments
7.2 Merck & Co
7.2.1 Merck & Co Company Summary
7.2.2 Merck & Co Business Overview
7.2.3 Merck & Co Oncology Immunotherapy Major Product Offerings
7.2.4 Merck & Co Oncology Immunotherapy Revenue in Global Market (2018-2023)
7.2.5 Merck & Co Key News & Latest Developments
7.3 Roche AG
7.3.1 Roche AG Company Summary
7.3.2 Roche AG Business Overview
7.3.3 Roche AG Oncology Immunotherapy Major Product Offerings
7.3.4 Roche AG Oncology Immunotherapy Revenue in Global Market (2018-2023)
7.3.5 Roche AG Key News & Latest Developments
7.4 AstraZeneca
7.4.1 AstraZeneca Company Summary
7.4.2 AstraZeneca Business Overview
7.4.3 AstraZeneca Oncology Immunotherapy Major Product Offerings
7.4.4 AstraZeneca Oncology Immunotherapy Revenue in Global Market (2018-2023)
7.4.5 AstraZeneca Key News & Latest Developments
7.5 Sanofi S.A.
7.5.1 Sanofi S.A. Company Summary
7.5.2 Sanofi S.A. Business Overview
7.5.3 Sanofi S.A. Oncology Immunotherapy Major Product Offerings
7.5.4 Sanofi S.A. Oncology Immunotherapy Revenue in Global Market (2018-2023)
7.5.5 Sanofi S.A. Key News & Latest Developments
7.6 Dendreon Pharmaceuticals
7.6.1 Dendreon Pharmaceuticals Company Summary
7.6.2 Dendreon Pharmaceuticals Business Overview
7.6.3 Dendreon Pharmaceuticals Oncology Immunotherapy Major Product Offerings
7.6.4 Dendreon Pharmaceuticals Oncology Immunotherapy Revenue in Global Market (2018-2023)
7.6.5 Dendreon Pharmaceuticals Key News & Latest Developments
7.7 Novartis
7.7.1 Novartis Company Summary
7.7.2 Novartis Business Overview
7.7.3 Novartis Oncology Immunotherapy Major Product Offerings
7.7.4 Novartis Oncology Immunotherapy Revenue in Global Market (2018-2023)
7.7.5 Novartis Key News & Latest Developments
7.8 Gilead Sciences Inc.
7.8.1 Gilead Sciences Inc. Company Summary
7.8.2 Gilead Sciences Inc. Business Overview
7.8.3 Gilead Sciences Inc. Oncology Immunotherapy Major Product Offerings
7.8.4 Gilead Sciences Inc. Oncology Immunotherapy Revenue in Global Market (2018-2023)
7.8.5 Gilead Sciences Inc. Key News & Latest Developments
7.9 Merck KGaA
7.9.1 Merck KGaA Company Summary
7.9.2 Merck KGaA Business Overview
7.9.3 Merck KGaA Oncology Immunotherapy Major Product Offerings
7.9.4 Merck KGaA Oncology Immunotherapy Revenue in Global Market (2018-2023)
7.9.5 Merck KGaA Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Oncology Immunotherapy Market Opportunities & Trends in Global Market
Table 2. Oncology Immunotherapy Market Drivers in Global Market
Table 3. Oncology Immunotherapy Market Restraints in Global Market
Table 4. Key Players of Oncology Immunotherapy in Global Market
Table 5. Top Oncology Immunotherapy Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Oncology Immunotherapy Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Oncology Immunotherapy Revenue Share by Companies, 2018-2023
Table 8. Global Companies Oncology Immunotherapy Product Type
Table 9. List of Global Tier 1 Oncology Immunotherapy Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Oncology Immunotherapy Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Oncology Immunotherapy Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Oncology Immunotherapy Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Oncology Immunotherapy Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Oncology Immunotherapy Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Oncology Immunotherapy Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Oncology Immunotherapy Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Oncology Immunotherapy Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Oncology Immunotherapy Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Oncology Immunotherapy Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Oncology Immunotherapy Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Oncology Immunotherapy Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Oncology Immunotherapy Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Oncology Immunotherapy Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Oncology Immunotherapy Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Oncology Immunotherapy Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Oncology Immunotherapy Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Oncology Immunotherapy Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Oncology Immunotherapy Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Oncology Immunotherapy Revenue, (US$, Mn), 2024-2030
Table 30. Bristol-Myers Squibb Company Summary
Table 31. Bristol-Myers Squibb Oncology Immunotherapy Product Offerings
Table 32. Bristol-Myers Squibb Oncology Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 33. Bristol-Myers Squibb Key News & Latest Developments
Table 34. Merck & Co Company Summary
Table 35. Merck & Co Oncology Immunotherapy Product Offerings
Table 36. Merck & Co Oncology Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 37. Merck & Co Key News & Latest Developments
Table 38. Roche AG Company Summary
Table 39. Roche AG Oncology Immunotherapy Product Offerings
Table 40. Roche AG Oncology Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 41. Roche AG Key News & Latest Developments
Table 42. AstraZeneca Company Summary
Table 43. AstraZeneca Oncology Immunotherapy Product Offerings
Table 44. AstraZeneca Oncology Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 45. AstraZeneca Key News & Latest Developments
Table 46. Sanofi S.A. Company Summary
Table 47. Sanofi S.A. Oncology Immunotherapy Product Offerings
Table 48. Sanofi S.A. Oncology Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 49. Sanofi S.A. Key News & Latest Developments
Table 50. Dendreon Pharmaceuticals Company Summary
Table 51. Dendreon Pharmaceuticals Oncology Immunotherapy Product Offerings
Table 52. Dendreon Pharmaceuticals Oncology Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 53. Dendreon Pharmaceuticals Key News & Latest Developments
Table 54. Novartis Company Summary
Table 55. Novartis Oncology Immunotherapy Product Offerings
Table 56. Novartis Oncology Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 57. Novartis Key News & Latest Developments
Table 58. Gilead Sciences Inc. Company Summary
Table 59. Gilead Sciences Inc. Oncology Immunotherapy Product Offerings
Table 60. Gilead Sciences Inc. Oncology Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 61. Gilead Sciences Inc. Key News & Latest Developments
Table 62. Merck KGaA Company Summary
Table 63. Merck KGaA Oncology Immunotherapy Product Offerings
Table 64. Merck KGaA Oncology Immunotherapy Revenue (US$, Mn) & (2018-2023)
Table 65. Merck KGaA Key News & Latest Developments
List of Figures
Figure 1. Oncology Immunotherapy Segment by Type in 2022
Figure 2. Oncology Immunotherapy Segment by Application in 2022
Figure 3. Global Oncology Immunotherapy Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Oncology Immunotherapy Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Oncology Immunotherapy Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Oncology Immunotherapy Revenue in 2022
Figure 8. By Type - Global Oncology Immunotherapy Revenue Market Share, 2018-2030
Figure 9. By Application - Global Oncology Immunotherapy Revenue Market Share, 2018-2030
Figure 10. By Type - Global Oncology Immunotherapy Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Oncology Immunotherapy Revenue Market Share, 2018-2030
Figure 12. By Application - Global Oncology Immunotherapy Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Oncology Immunotherapy Revenue Market Share, 2018-2030
Figure 14. By Region - Global Oncology Immunotherapy Revenue Market Share, 2018-2030
Figure 15. By Country - North America Oncology Immunotherapy Revenue Market Share, 2018-2030
Figure 16. US Oncology Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Oncology Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Oncology Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Oncology Immunotherapy Revenue Market Share, 2018-2030
Figure 20. Germany Oncology Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 21. France Oncology Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Oncology Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Oncology Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Oncology Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Oncology Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Oncology Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Oncology Immunotherapy Revenue Market Share, 2018-2030
Figure 28. China Oncology Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Oncology Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Oncology Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Oncology Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 32. India Oncology Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Oncology Immunotherapy Revenue Market Share, 2018-2030
Figure 34. Brazil Oncology Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Oncology Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Oncology Immunotherapy Revenue Market Share, 2018-2030
Figure 37. Turkey Oncology Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Oncology Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Oncology Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Oncology Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 41. Bristol-Myers Squibb Oncology Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Merck & Co Oncology Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Roche AG Oncology Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. AstraZeneca Oncology Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Sanofi S.A. Oncology Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Dendreon Pharmaceuticals Oncology Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Novartis Oncology Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Gilead Sciences Inc. Oncology Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Merck KGaA Oncology Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
